**Core Concept**
The underlying condition in this case is a type of lymphoma, specifically a B-cell lymphoma variant, which is being treated with chemotherapy. However, the patient's symptoms suggest that the treatment is causing a specific side effect.

**Why the Correct Answer is Right**
The patient is likely experiencing a condition known as hemorrhagic cystitis, which is a common side effect of certain chemotherapeutic agents, particularly cyclophosphamide. This condition occurs due to the toxic effects of acrolein, a metabolite of cyclophosphamide, on the bladder mucosa. The use of a specific supplement, mesna, can help prevent this side effect by binding to acrolein and reducing its toxicity.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because mesna is a specific antidote for hemorrhagic cystitis caused by cyclophosphamide, and supplementation with this drug is the correct answer.
**Option B:** This option is incorrect because there is no evidence to suggest that supplementation with this drug would prevent hemorrhagic cystitis.
**Option C:** This option is incorrect because while hydration is an important aspect of preventing side effects from chemotherapy, it is not a specific supplement that would prevent hemorrhagic cystitis.
**Option D:** This option is incorrect because this drug is not typically used to prevent hemorrhagic cystitis.

**Clinical Pearl / High-Yield Fact**
When treating patients with cyclophosphamide, it is essential to consider the risk of hemorrhagic cystitis and to supplement with mesna to prevent this side effect. This is a classic example of a high-yield fact that can be remembered using the mnemonic "Cyclophosphamide-induced hemorrhagic cystitis: Mesna prevents it."

**Correct Answer:** A. Mesna.